Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment


                 of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2021, the Board of Directors (the "Board") of Insulet Corporation (the "Company") increased the authorized number of directors of the Company from nine to 10 and appointed Luciana Borio, M.D. as a Class I director to fill the newly created vacancy. Dr. Borio will stand for election by stockholders at the Company's 2023 Annual Meeting of Stockholders. Dr. Borio has not been named to any committees of the Board.

Since July 2021, Dr. Borio has been a venture partner at ARCH Venture Partners, where she advises on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs. She previously served as Senior Vice President of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, from 2019 to 2020, and served as a member of the President's Transition COVID-19 Advisory Board. Previously, Dr. Borio served as Director, Medical and Biodefense Preparedness Policy, for the National Security Council from 2017 to 2019. Prior to that, Dr. Borio spent nearly 10 years at the United States Food and Drug Administration in roles of increasing responsibility, including Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy. Dr. Borio earned a B.S. in Zoology from George Washington University and an M.D. from George Washington University School of Medicine.

There are no arrangements or understandings between Dr. Borio and any other persons pursuant to which Dr. Borio was selected as a director and there are no transactions involving Dr. Borio required to be disclosed under Item 404(a) of Regulation S-K. As a non-employee director of the Company, Dr. Borio will receive cash and equity compensation pursuant to the Company's non-employee director compensation program, as described in the Company's proxy statement filed with the Securities and Exchange Commission on April 13, 2021, as may be adjusted by the Board from time to time.

On October 15, 2021, Sally W. Crawford, a member of the Company's Board of Directors, notified the Company of her decision to retire from the Board effective December 31, 2021. Ms. Crawford's decision to step down from the Board, which will mark her retirement from the Board after 13 years of distinguished service, did not involve any disagreement with other Board members or with management.

Item 7.01 Regulation FD Disclosures.

On October 18, 2021 the Company issued a press release announcing Dr. Borio's appointment to the Board and Ms. Crawford's retirement. A copy of that press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.




   (d)   Exhibits.



  Exhibit
    No.        Description

   99.1        Press Release dated October 18, 2021
    104        Cover Page Interactive Date File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses